- Trials with a EudraCT protocol (272)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
272 result(s) found for: Double pneumonia.
Displaying page 1 of 14.
EudraCT Number: 2014-001097-34 | Sponsor Protocol Number: CD-ID-MEDI4893-1139 | Start Date*: 2014-09-08 | |||||||||||
Sponsor Name:MedImmune, LLC | |||||||||||||
Full Title: A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha To... | |||||||||||||
Medical condition: Prevention of Staphyloccus aureus pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GR (Completed) DE (Completed) ES (Completed) CZ (Completed) PT (Completed) HU (Completed) GB (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016069-27 | Sponsor Protocol Number: DORIPED3003 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | |||||||||||||
Medical condition: Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000101-12 | Sponsor Protocol Number: 111654 | Start Date*: 2015-05-11 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, multi-centre, double-blind, randomised study to assess the non-inferiority of a commercial lot of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vacc... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three-dose primary vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases, either a two-dose or t... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000557-21 | Sponsor Protocol Number: 107007 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IIIb randomized, double-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine compar... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005828-11 | Sponsor Protocol Number: SAVE-MORE | Start Date*: 2020-12-16 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE-MORE DOUBLE-BLIND, RANDOMIZED, PHASE III CONFIRMATORY TRIAL | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003343-29 | Sponsor Protocol Number: RG_12-179 | Start Date*: 2013-01-18 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Simvastatin as adjuvant therapy to correct neutrophil dysfunction in older pneumonia patients - a randomised double blind placebo controlled trial | |||||||||||||
Medical condition: Acute episodes of Pneumonia and sepsis in older adults | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006764-29 | Sponsor Protocol Number: KB001-04 | Start Date*: 2008-03-14 | |||||||||||
Sponsor Name:KaloBios Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, double-blind, placebo-controlled pilot study of KB001 in mechanically-ventilated patients colonized with pseudomonas aeruginosa | |||||||||||||
Medical condition: Patients with Pseudomonas aeruginosa Ventilator-Associated Pulmonary Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003406-14 | Sponsor Protocol Number: UHNM1219 | Start Date*: 2017-09-26 | |||||||||||||||||||||
Sponsor Name:University Hospital of North Midlands NHS Trust | |||||||||||||||||||||||
Full Title: The Metoclopramoide and selective oral decontamination for Avoiding Pneumonia after Stroke (MAPS-2) Trial: a 2x2 double-blind, randomized controlled trial of metoclopramide and selective oral decon... | |||||||||||||||||||||||
Medical condition: Stroke We are testing two differnt intervetnions which could prevent pneumonia in stroke patietns. Prevention pneumonia could potentiallly speed up recovery and improve survival. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005079-17 | Sponsor Protocol Number: 06-IN-AK004 | Start Date*: 2007-02-19 | |||||||||||
Sponsor Name:Nektar Therapeutics | |||||||||||||
Full Title: An Open-Label, Multicenter, Multinational Study to Assess the Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-Ventilated Patients with Nosocomial Pne... | |||||||||||||
Medical condition: Nosocomial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004542-18 | Sponsor Protocol Number: V114-002 | Start Date*: 2012-04-04 | ||||||||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX ™ 23) and ... | ||||||||||||||||||||||||||||
Medical condition: prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, 1, 5, 7F, 3, 6A, 19A, 22F,... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SE (Completed) ES (Completed) PL (Completed) DK (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004782-92 | Sponsor Protocol Number: NAB-BC-3781-3102 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia | |||||||||||||
Medical condition: Community-acquired bacterial pneumonia (CABP) is a commonly occurring serious infection that requires systemic antibiotic therapy and is associated with substantial morbidity, mortality, and consid... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015103-58 | Sponsor Protocol Number: V114-001 | Start Date*: 2010-01-14 | |||||||||||||||||||||||||||||||
Sponsor Name:MSD Finland Oy | |||||||||||||||||||||||||||||||||
Full Title: A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of Pneumococcal Conjugate Vaccine (V114) Compared to Prevnar™ in Healthy Adults and Toddlers | |||||||||||||||||||||||||||||||||
Medical condition: Prevention of pneumococcal invasive disease, pneumococcal pneumonia, and otitis media caused by S. pneumoniae due to capsular serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, 1, 5, 7F, 3... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002390-28 | Sponsor Protocol Number: INSPIRE | Start Date*: 2022-10-10 | ||||||||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | ||||||||||||||||||
Full Title: IMMUNOTHERAPY NAVIGATED BY SERUM PRESEPSIN FOR INFECTIONS OF THE RESPIRATORY TRACT: THE INSPIRE DOUBLE-BLIND, RANDOMIZED, PHASE IIa EXPLORATORY TRIAL | ||||||||||||||||||
Medical condition: community-acquired pneumonia, hospital-acquired pneumonia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003109-28 | Sponsor Protocol Number: ICLA-20-PNE1 | Start Date*: 2007-09-28 | |||||||||||
Sponsor Name:Arpida AG | |||||||||||||
Full Title: Randomized, double-blind, multicenter study to evaluate efficacy and safety of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-as... | |||||||||||||
Medical condition: Hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or health-care-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LV (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005247-78 | Sponsor Protocol Number: OB003 | Start Date*: 2022-01-19 | |||||||||||
Sponsor Name:Oxygen Biotech s.r.o. | |||||||||||||
Full Title: A 2-Part, Open-label, Non-randomized (Part A) and Randomized, Double-blinded, Placebo-controlled (Part B) multicentric, international study with adaptive design to evaluate safety and tolerability ... | |||||||||||||
Medical condition: COVID-19 patients suffering from moderate to severe pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002855-13 | Sponsor Protocol Number: CAP-01-102 | Start Date*: 2014-02-14 | |||||||||||
Sponsor Name:Cardeas Pharma | |||||||||||||
Full Title: A Randomized Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered via the Investigational eFlow® Inline System in Mechanically Ventilated... | |||||||||||||
Medical condition: Gram-negative Bacterial Pneumonia in Mechanically Ventilated Patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) GR (Completed) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004979-14 | Sponsor Protocol Number: AR-320-003 | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:Aridis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention o... | |||||||||||||
Medical condition: Prevention of nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) BE (Completed) NL (Completed) PT (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005169-63 | Sponsor Protocol Number: NAB-BC-3781-3101 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) HU (Completed) LV (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002902-31 | Sponsor Protocol Number: 0015 | Start Date*: 2005-11-09 | |||||||||||
Sponsor Name:Theravance, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infec... | |||||||||||||
Medical condition: Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) BE (Completed) DE (Completed) MT (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001665-20 | Sponsor Protocol Number: BCAR-RESP-SE21 | Start Date*: 2021-04-20 | |||||||||||
Sponsor Name:Semmelweis University Department of Oralbiology | |||||||||||||
Full Title: Prospective, randomized, controlled, double-blinded study on the efficacy of nebulized 4.2% sodium-bicarbonate in COVID-19 pneumonia | |||||||||||||
Medical condition: severe COVID-19 pneumonia requires invasive ventillatory support | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
